{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T12:18:32Z","timestamp":1793881112934,"version":"4.7.0"},"reference-count":50,"publisher":"American Medical Association (AMA)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2023,11,1]]},"abstract":"\n Importance<\/jats:title>\n Germline gene panel testing is recommended for men with advanced prostate cancer (PCa) or a family history of cancer. While evidence is limited for some genes currently included in panel testing, gene panels are also likely to be incomplete and missing genes that influence PCa risk and aggressive disease.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To identify genes associated with aggressive PCa.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n A 2-stage exome sequencing case-only genetic association study was conducted including men of European ancestry from 18 international studies. Data analysis was performed from January 2021 to March 2023. Participants were 9185 men with aggressive PCa (including 6033 who died of PCa and 2397 with confirmed metastasis) and 8361 men with nonaggressive PCa.<\/jats:p>\n <\/jats:sec>\n \n Exposure<\/jats:title>\n Sequencing data were evaluated exome-wide and in a focused investigation of 29 DNA repair pathway and cancer susceptibility genes, many of which are included on gene panels.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n The primary study outcomes were aggressive (category T4 or both T3 and Gleason score \u22658 tumors, metastatic PCa, or PCa death) vs nonaggressive PCa (category T1 or T2 and Gleason score \u22646 tumors without known recurrence), and metastatic vs nonaggressive PCa.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n A total of 17\u202f546 men of European ancestry were included in the analyses; mean (SD) age at diagnosis was 65.1 (9.2) years in patients with aggressive PCa and 63.7 (8.0) years in those with nonaggressive disease. The strongest evidence of association with aggressive or metastatic PCa was noted for rare deleterious variants in known PCa risk genes\n BRCA2<\/jats:italic>\n and\n ATM<\/jats:italic>\n (\n P<\/jats:italic>\n \u2009\u2264\u20091.9\u2009\u00d7\u200910\n \u22126<\/jats:sup>\n ), followed by\n NBN<\/jats:italic>\n (\n P<\/jats:italic>\n \u2009=\u20091.7\u2009\u00d7\u200910\n \u22124<\/jats:sup>\n ). This study found nominal evidence (\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.05) of association with rare deleterious variants in\n MSH2<\/jats:italic>\n ,\n XRCC2<\/jats:italic>\n , and\n MRE11A<\/jats:italic>\n . Five other genes had evidence of greater risk (OR\u22652) but carrier frequency differences between aggressive and nonaggressive PCa were not statistically significant:\n TP53<\/jats:italic>\n ,\n RAD51D<\/jats:italic>\n ,\n BARD1<\/jats:italic>\n ,\n GEN1<\/jats:italic>\n , and\n SLX4<\/jats:italic>\n . Deleterious variants in these 11 candidate genes were carried by 2.3% of patients with nonaggressive, 5.6% with aggressive, and 7.0% with metastatic PCa.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n The findings of this study provide further support for DNA repair and cancer susceptibility genes to better inform disease management in men with PCa and for extending testing to men with nonaggressive disease, as men carrying deleterious alleles in these genes are likely to develop more advanced disease.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamaoncol.2023.3482","type":"journal-article","created":{"date-parts":[[2023,9,21]],"date-time":"2023-09-21T11:01:04Z","timestamp":1695294064000},"page":"1514","source":"Crossref","is-referenced-by-count":47,"title":["Germline Sequencing Analysis to Inform Clinical Gene Panel Testing for Aggressive Prostate Cancer"],"prefix":"10.1001","volume":"9","author":[{"given":"Burcu F.","family":"Darst","sequence":"first","affiliation":[{"name":"Center for Genetic Epidemiology, Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles"},{"name":"Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ed","family":"Saunders","sequence":"additional","affiliation":[{"name":"The Institute of Cancer Research, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tokhir","family":"Dadaev","sequence":"additional","affiliation":[{"name":"The Institute of Cancer Research, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Sheng","sequence":"additional","affiliation":[{"name":"Center for Genetic Epidemiology, Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peggy","family":"Wan","sequence":"additional","affiliation":[{"name":"Center for Genetic Epidemiology, Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loreall","family":"Pooler","sequence":"additional","affiliation":[{"name":"Center for Genetic Epidemiology, Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy Y.","family":"Xia","sequence":"additional","affiliation":[{"name":"Center for Genetic Epidemiology, Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Chanock","sequence":"additional","affiliation":[{"name":"Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonja I.","family":"Berndt","sequence":"additional","affiliation":[{"name":"Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Population Science, American Cancer Society, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alpa V.","family":"Patel","sequence":"additional","affiliation":[{"name":"Department of Population Science, American Cancer Society, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Demetrius","family":"Albanes","sequence":"additional","affiliation":[{"name":"Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie J.","family":"Weinstein","sequence":"additional","affiliation":[{"name":"Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Gnanapragasam","sequence":"additional","affiliation":[{"name":"Division of Urology, Department of Surgery, University of Cambridge, Cambridge, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chad","family":"Huff","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fergus J.","family":"Couch","sequence":"additional","affiliation":[{"name":"Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota"},{"name":"Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicja","family":"Wolk","sequence":"additional","affiliation":[{"name":"Karolinska Institute, Solna, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graham G.","family":"Giles","sequence":"additional","affiliation":[{"name":"Cancer Epidemiology Division, Cancer Council Victoria, Melbourne, Victoria, Australia"},{"name":"Precision Medicine, School of Clinical Sciences at Monash Health, Monash University, Melbourne, Victoria, Australia"},{"name":"Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, University of Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tu","family":"Nguyen-Dumont","sequence":"additional","affiliation":[{"name":"Precision Medicine, School of Clinical Sciences at Monash Health, Monash University, Melbourne, Victoria, Australia"},{"name":"Department of Clinical Pathology, The University of Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger L.","family":"Milne","sequence":"additional","affiliation":[{"name":"Cancer Epidemiology Division, Cancer Council Victoria, Melbourne, Victoria, Australia"},{"name":"Precision Medicine, School of Clinical Sciences at Monash Health, Monash University, Melbourne, Victoria, Australia"},{"name":"Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, University of Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark M.","family":"Pomerantz","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie A.","family":"Schmidt","sequence":"additional","affiliation":[{"name":"Cancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom"},{"name":"Department of Clinical Epidemiology, Department of Clinical Medicine, Aarhus University Hospital and Aarhus University, Aarhus N, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth C.","family":"Travis","sequence":"additional","affiliation":[{"name":"Cancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy J.","family":"Key","sequence":"additional","affiliation":[{"name":"Cancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konrad H.","family":"Stopsack","sequence":"additional","affiliation":[{"name":"Harvard T. H. Chan School of Public Health, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorelei A.","family":"Mucci","sequence":"additional","affiliation":[{"name":"Harvard T. H. Chan School of Public Health, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William J.","family":"Catalona","sequence":"additional","affiliation":[{"name":"Northwestern University Feinberg School of Medicine, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth","family":"Marosy","sequence":"additional","affiliation":[{"name":"Center for Inherited Disease Research, Department of Genetic Medicine, Johns Hopkins School of Medicine, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kurt N.","family":"Hetrick","sequence":"additional","affiliation":[{"name":"Center for Inherited Disease Research, Department of Genetic Medicine, Johns Hopkins School of Medicine, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly F.","family":"Doheny","sequence":"additional","affiliation":[{"name":"Center for Inherited Disease Research, Department of Genetic Medicine, Johns Hopkins School of Medicine, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"MacInnis","sequence":"additional","affiliation":[{"name":"Cancer Epidemiology Division, Cancer Council Victoria, Melbourne, Victoria, Australia"},{"name":"Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, University of Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa C.","family":"Southey","sequence":"additional","affiliation":[{"name":"Cancer Epidemiology Division, Cancer Council Victoria, Melbourne, Victoria, Australia"},{"name":"Precision Medicine, School of Clinical Sciences at Monash Health, Monash University, Melbourne, Victoria, Australia"},{"name":"Department of Clinical Pathology, The University of Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosalind A.","family":"Eeles","sequence":"additional","affiliation":[{"name":"The Institute of Cancer Research, London, United Kingdom"},{"name":"Royal Marsden NHS Foundation Trust, Fulham Road, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fredrik","family":"Wiklund","sequence":"additional","affiliation":[{"name":"Karolinska Institute, Solna, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David V.","family":"Conti","sequence":"additional","affiliation":[{"name":"Center for Genetic Epidemiology, Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zsofia","family":"Kote-Jarai","sequence":"additional","affiliation":[{"name":"The Institute of Cancer Research, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher A.","family":"Haiman","sequence":"additional","affiliation":[{"name":"Center for Genetic Epidemiology, Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"12","key":"coi230044r1","first-page":"1288","article-title":"NCCN guidelines insights: prostate cancer, version 1.2023.","volume":"20","author":"Schaeffer","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"issue":"5","key":"coi230044r2","doi-asserted-by":"publisher","first-page":"479","DOI":"10.6004\/jnccn.2019.0023","article-title":"Prostate cancer, version 2.2019, NCCN Clinical Practice Guidelines in Oncology.","volume":"17","author":"Mohler","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"issue":"24","key":"coi230044r3","doi-asserted-by":"publisher","first-page":"2798","DOI":"10.1200\/JCO.20.00046","article-title":"Implementation of germline testing for prostate cancer: Philadelphia Prostate Cancer Consensus Conference 2019.","volume":"38","author":"Giri","year":"2020","journal-title":"J Clin Oncol"},{"issue":"5","key":"coi230044r4","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1093\/jnci\/djaa132","article-title":"Germline sequencing DNA repair genes in 5545 men with aggressive and nonaggressive prostate cancer.","volume":"113","author":"Darst","year":"2021","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"coi230044r5","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1056\/NEJMoa1603144","article-title":"Inherited DNA-repair gene mutations in men with metastatic prostate cancer.","volume":"375","author":"Pritchard","year":"2016","journal-title":"N Engl J Med"},{"issue":"1","key":"coi230044r6","article-title":"DNA repair pathways and their association with lethal prostate cancer in African American and European American men.","volume":"6","author":"Plym","year":"2021","journal-title":"J Natl Cancer Inst Cancer Spectr"},{"issue":"13","key":"coi230044r7","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1002\/pros.24195","article-title":"Observed evidence for guideline-recommended genes in predicting prostate cancer risk from a large population-based cohort.","volume":"81","author":"Wei","year":"2021","journal-title":"Prostate"},{"key":"coi230044r8","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1200\/PO.19.00179","article-title":"Pathogenic variants in cancer predisposition genes and prostate cancer risk in men of African ancestry.","volume":"4","author":"Matejcic","year":"2020","journal-title":"JCO Precis Oncol"},{"issue":"7","key":"coi230044r9","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1002\/pros.24123","article-title":"Comparison of germline mutations in African American and Caucasian men with metastatic prostate cancer.","volume":"81","author":"Ledet","year":"2021","journal-title":"Prostate"},{"issue":"6","key":"coi230044r10","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1093\/jnci\/djaa154","article-title":"Recommended definitions of aggressive prostate cancer for etiologic epidemiologic research.","volume":"113","author":"Hurwitz","year":"2021","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"coi230044r11","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s13059-016-0974-4","article-title":"The Ensembl variant effect predictor.","volume":"17","author":"McLaren","year":"2016","journal-title":"Genome Biol"},{"issue":"database issue","key":"coi230044r12","doi-asserted-by":"publisher","first-page":"D980","DOI":"10.1093\/nar\/gkt1113","article-title":"ClinVar: public archive of relationships among sequence variation and human phenotype.","volume":"42","author":"Landrum","year":"2014","journal-title":"Nucleic Acids Res"},{"issue":"4","key":"coi230044r13","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/j.ajhg.2016.08.016","article-title":"REVEL: an ensemble method for predicting the pathogenicity of rare missense variants.","volume":"99","author":"Ioannidis","year":"2016","journal-title":"Am J Hum Genet"},{"issue":"1","key":"coi230044r14","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1038\/s41416-018-0141-7","article-title":"Rare germline variants in DNA repair genes and the angiogenesis pathway predispose prostate cancer patients to develop metastatic disease.","volume":"119","author":"Mijuskovic","year":"2018","journal-title":"Br J Cancer"},{"issue":"6","key":"coi230044r15","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1038\/bjc.2014.30","article-title":"Frequent germline deleterious mutations in DNA repair genes in familial prostate cancer cases are associated with advanced disease.","volume":"110","author":"Leongamornlert","year":"2014","journal-title":"Br J Cancer"},{"issue":"3","key":"coi230044r16","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.eururo.2019.01.050","article-title":"Germline DNA repair gene mutations in young-onset prostate cancer cases in the UK: evidence for a more extensive genetic panel.","volume":"76","author":"Leongamornlert","year":"2019","journal-title":"Eur Urol"},{"issue":"5","key":"coi230044r17","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.eururo.2016.11.033","article-title":"Germline mutations in ATM and BRCA1\/2 distinguish risk for lethal and indolent prostate cancer and are associated with early age at death.","volume":"71","author":"Na","year":"2017","journal-title":"Eur Urol"},{"issue":"4","key":"coi230044r18","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2015-010332","article-title":"Determining the frequency of pathogenic germline variants from exome sequencing in patients with castrate-resistant prostate cancer.","volume":"6","author":"Hart","year":"2016","journal-title":"BMJ Open"},{"issue":"18","key":"coi230044r19","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1056\/NEJMoa1506859","article-title":"DNA-repair defects and olaparib in metastatic prostate cancer.","volume":"373","author":"Mateo","year":"2015","journal-title":"N Engl J Med"},{"issue":"5507","key":"coi230044r20","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1126\/science.1056154","article-title":"Human DNA repair genes.","volume":"291","author":"Wood","year":"2001","journal-title":"Science"},{"issue":"8","key":"coi230044r21","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1038\/bjc.2016.50","article-title":"Gene and pathway level analyses of germline DNA-repair gene variants and prostate cancer susceptibility using the iCOGS-genotyping array.","volume":"114","author":"Saunders","year":"2016","journal-title":"Br J Cancer"},{"issue":"9","key":"coi230044r22","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1093\/jnci\/djs177","article-title":"A DNA repair pathway-focused score for prediction of outcomes in ovarian cancer treated with platinum-based chemotherapy.","volume":"104","author":"Kang","year":"2012","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"coi230044r23","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.canlet.2012.01.003","article-title":"PTEN in DNA damage repair.","volume":"319","author":"Ming","year":"2012","journal-title":"Cancer Lett"},{"key":"coi230044r24","doi-asserted-by":"publisher","first-page":"14248","DOI":"10.1038\/ncomms14248","article-title":"Genome-wide association study of prostate-specific antigen levels identifies novel loci independent of prostate cancer.","volume":"8","author":"Hoffmann","year":"2017","journal-title":"Nat Commun"},{"issue":"3","key":"coi230044r25","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/S0092-8674(00)81174-5","article-title":"Nibrin, a novel DNA double-strand break repair protein, is mutated in Nijmegen breakage syndrome.","volume":"93","author":"Varon","year":"1998","journal-title":"Cell"},{"issue":"1","key":"coi230044r26","doi-asserted-by":"publisher","first-page":"2573","DOI":"10.1038\/s41467-020-16141-8","article-title":"High-throughput functional evaluation of BRCA2 variants of unknown significance.","volume":"11","author":"Ikegami","year":"2020","journal-title":"Nat Commun"},{"issue":"4","key":"coi230044r27","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1016\/j.euo.2020.12.001","article-title":"Rare germline variants in ATM predispose to prostate cancer: a PRACTICAL consortium study.","volume":"4","author":"Karlsson","year":"2021","journal-title":"Eur Urol Oncol"},{"issue":"4","key":"coi230044r28","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1038\/s41391-021-00466-6","article-title":"KLK3 germline mutation I179T complements DNA repair genes for predicting prostate cancer progression.","volume":"25","author":"Xu","year":"2022","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"4","key":"coi230044r29","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s00439-015-1534-9","article-title":"Associations of prostate cancer risk variants with disease aggressiveness: results of the NCI-SPORE Genetics Working Group analysis of 18,343 cases.","volume":"134","author":"Helfand","year":"2015","journal-title":"Hum Genet"},{"issue":"5","key":"coi230044r30","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/j.eururo.2018.01.010","article-title":"Clinical outcome of prostate cancer patients with germline DNA repair mutations: retrospective analysis from an international study.","volume":"73","author":"Mateo","year":"2018","journal-title":"Eur Urol"},{"issue":"2","key":"coi230044r31","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.euo.2019.12.003","article-title":"Rare germline pathogenic mutations of DNA repair genes are most strongly associated with grade group 5 prostate cancer.","volume":"3","author":"Wu","year":"2020","journal-title":"Eur Urol Oncol"},{"issue":"1","key":"coi230044r32","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1002\/pros.24252","article-title":"Association of germline rare pathogenic mutations in guideline-recommended genes with prostate cancer progression: a meta-analysis.","volume":"82","author":"Shi","year":"2022","journal-title":"Prostate"},{"issue":"3","key":"coi230044r33","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.4143\/crt.2018.532","article-title":"Inherited NBN mutations and prostate cancer risk and survival.","volume":"51","author":"Rusak","year":"2019","journal-title":"Cancer Res Treat"},{"issue":"3","key":"coi230044r34","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.eururo.2021.10.036","article-title":"Inherited TP53 variants and risk of prostate cancer.","volume":"81","author":"Maxwell","year":"2022","journal-title":"Eur Urol"},{"issue":"11","key":"coi230044r35","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1016\/S1470-2045(21)00522-2","article-title":"A prospective prostate cancer screening programme for men with pathogenic variants in mismatch repair genes (IMPACT): initial results from an international prospective study.","volume":"22","author":"Bancroft","year":"2021","journal-title":"Lancet Oncol"},{"issue":"3","key":"coi230044r36","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.3892\/or.2015.4080","article-title":"Expression of DNA ligase IV is linked to poor prognosis and characterizes a subset of prostate cancers harboring TMPRSS2:ERG fusion and PTEN deletion.","volume":"34","author":"Grupp","year":"2015","journal-title":"Oncol Rep"},{"issue":"1","key":"coi230044r37","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/s41698-022-00291-7","article-title":"PALB2 or BARD1 loss confers homologous recombination deficiency and PARP inhibitor sensitivity in prostate cancer.","volume":"6","author":"Dillon","year":"2022","journal-title":"NPJ Precis Oncol"},{"issue":"18","key":"coi230044r38","doi-asserted-by":"publisher","first-page":"4333","DOI":"10.7150\/jca.31454","article-title":"Elevated MRE11 expression associated with progression and poor outcome in prostate cancer.","volume":"10","author":"Wang","year":"2019","journal-title":"J Cancer"},{"issue":"1","key":"coi230044r39","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.cell.2009.06.030","article-title":"Mammalian BTBD12\/SLX4 assembles a Holliday junction resolvase and is required for DNA repair.","volume":"138","author":"Svendsen","year":"2009","journal-title":"Cell"},{"issue":"2","key":"coi230044r40","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1038\/ng.750","article-title":"Mutations of the SLX4 gene in Fanconi anemia.","volume":"43","author":"Kim","year":"2011","journal-title":"Nat Genet"},{"issue":"14","key":"coi230044r41","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1200\/JCO.2012.44.1238","article-title":"Elevated risk of prostate cancer among men with Lynch syndrome.","volume":"31","author":"Raymond","year":"2013","journal-title":"J Clin Oncol"},{"issue":"4","key":"coi230044r42","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1159\/000081443","article-title":"Analysis of candidate genes for prostate cancer.","volume":"57","author":"Burmester","year":"2004","journal-title":"Hum Hered"},{"issue":"2","key":"coi230044r43","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1038\/nrc2998","article-title":"DNA polymerases and cancer.","volume":"11","author":"Lange","year":"2011","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"coi230044r44","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1038\/ng.2503","article-title":"Germline mutations affecting the proofreading domains of POLE and POLD1 predispose to colorectal adenomas and carcinomas.","volume":"45","author":"Palles","year":"2013","journal-title":"Nat Genet"},{"issue":"25","key":"coi230044r45","doi-asserted-by":"publisher","first-page":"2394","DOI":"10.1056\/NEJMoa2105215","article-title":"Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer.","volume":"384","author":"Tutt","year":"2021","journal-title":"N Engl J Med"},{"issue":"6","key":"coi230044r46","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1056\/NEJMoa1706450","article-title":"Olaparib for metastatic breast cancer in patients with a germline BRCA mutation.","volume":"377","author":"Robson","year":"2017","journal-title":"N Engl J Med"},{"issue":"9737","key":"coi230044r47","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/S0140-6736(10)60893-8","article-title":"Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial.","volume":"376","author":"Audeh","year":"2010","journal-title":"Lancet"},{"issue":"3","key":"coi230044r48","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1200\/JCO.2014.56.2728","article-title":"Olaparib monotherapy in patients with advanced cancer and a germline BRCA1\/2 mutation.","volume":"33","author":"Kaufman","year":"2015","journal-title":"J Clin Oncol"},{"issue":"22","key":"coi230044r49","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","article-title":"Olaparib for metastatic castration-resistant prostate cancer.","volume":"382","author":"de Bono","year":"2020","journal-title":"N Engl J Med"},{"issue":"8","key":"coi230044r50","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1038\/bjc.2011.383","article-title":"BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: implications for genetic testing in prostate cancer patients.","volume":"105","author":"Kote-Jarai","year":"2011","journal-title":"Br J Cancer"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/articlepdf\/2809874\/jamaoncology_darst_2023_oi_230044_1733525778.27724.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T18:30:18Z","timestamp":1733509818000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2809874"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,1]]},"references-count":50,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2023.3482","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11,1]]}}}